{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T21:05:18Z","timestamp":1775077518817,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2001,1,1]],"date-time":"2001-01-01T00:00:00Z","timestamp":978307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological Psychiatry"],"published-print":{"date-parts":[[2001,1]]},"DOI":"10.1016\/s0006-3223(00)01026-x","type":"journal-article","created":{"date-parts":[[2002,7,25]],"date-time":"2002-07-25T17:14:12Z","timestamp":1027617252000},"page":"52-63","source":"Crossref","is-referenced-by-count":165,"title":["Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine"],"prefix":"10.1016","volume":"49","author":[{"given":"Gary D","family":"Tollefson","sequence":"first","affiliation":[]},{"given":"Martin A","family":"Birkett","sequence":"additional","affiliation":[]},{"given":"Gerilyn M","family":"Kiesler","sequence":"additional","affiliation":[]},{"given":"Andrew J","family":"Wood","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S0006-3223(00)01026-X_BIB1","unstructured":"Association for Methodology and Documentation in Psychiatry [Arbeltsgemeinschaft fur Methodik und Dokumentation in der Psychiatrie] (1981): Das AMDP-System: Manual zur Documentation Psychiatriacher Befunde 4 (AMDP). Berlin: Auflage."},{"key":"10.1016\/S0006-3223(00)01026-X_BIB2","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br J Psychiatry"},{"key":"10.1016\/S0006-3223(00)01026-X_BIB3","doi-asserted-by":"crossref","unstructured":"Beasley CM Jr, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S (1996): Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 124:159\u2013167.","DOI":"10.1007\/BF02245617"},{"key":"10.1016\/S0006-3223(00)01026-X_BIB4","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0893-133X(94)00129-N","article-title":"Radioreceptor binding profile of the atypical antipsychotic olanzapine","volume":"14","author":"Bymaster","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/S0006-3223(00)01026-X_BIB5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0893-133X(88)90012-7","article-title":"The current status of the dopamine hypothesis of schizophrenia","volume":"1","author":"Carlsson","year":"1988","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/S0006-3223(00)01026-X_BIB6","doi-asserted-by":"crossref","first-page":"21S","DOI":"10.1097\/00004714-198808001-00005","article-title":"A 5-year prospective longitudinal study of tardive dyskinesia","volume":"8","author":"Chouinard","year":"1988","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/S0006-3223(00)01026-X_BIB7","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1192\/bjp.136.5.413","article-title":"The natural history of schizophrenia in the long-term","volume":"136","author":"Ciompi","year":"1980","journal-title":"Br J Psychiatry"},{"key":"10.1016\/S0006-3223(00)01026-X_BIB8","first-page":"269","article-title":"Clozapine efficacy in schizophrenic nonresponders","volume":"24","author":"Conley","year":"1988","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/S0006-3223(00)01026-X_BIB9","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1176\/ajp.155.7.914","article-title":"Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia","volume":"155","author":"Conley","year":"1998","journal-title":"Am J Psychiatry"},{"key":"10.1016\/S0006-3223(00)01026-X_BIB10","first-page":"1203","article-title":"From noncompliance to collaboration in the treatment of schizophrenia","volume":"41","author":"Corrigan","year":"1990","journal-title":"Hosp Community Psychiatry"},{"key":"10.1016\/S0006-3223(00)01026-X_BIB11","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1192\/S0007125000296840","article-title":"General pharmacology of clozapine","volume":"160","author":"Coward","year":"1992","journal-title":"Br J Psychiatry"},{"key":"10.1016\/S0006-3223(00)01026-X_BIB12","unstructured":"Dossenbach MRK, Tollefson GD, Kratky P, Beuzen JN (in press): Evidence for the effectiveness of olanzapine among treatment refractory patients non-responsive and\/or intolerant to clozapine. Clin Ther."},{"key":"10.1016\/S0006-3223(00)01026-X_BIB13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00315342","article-title":"Clinical and statistical issues in therapeutic equivalence trials","volume":"45","author":"Garbe","year":"1993","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/S0006-3223(00)01026-X_BIB14","doi-asserted-by":"crossref","unstructured":"Guy W (1976): ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: U.S. Department of Health, Education and Welfare.","DOI":"10.1037\/e591322011-001"},{"key":"10.1016\/S0006-3223(00)01026-X_BIB15","doi-asserted-by":"crossref","unstructured":"Guy W, Ban TA (1982): The AMDP System. Berlin: Springer.","DOI":"10.1007\/978-3-642-68405-0"},{"key":"10.1016\/S0006-3223(00)01026-X_BIB16","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1136\/bmj.306.6890.1427","article-title":"Clozapine","volume":"306","author":"Hirsch","year":"1993","journal-title":"Br Med J"},{"key":"10.1016\/S0006-3223(00)01026-X_BIB17","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/S0006-3223(00)01026-X_BIB18","first-page":"322","article-title":"The current status of neuroleptic therapy","volume":"50","author":"Kane","year":"1989","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/S0006-3223(00)01026-X_BIB19","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJM199601043340109","article-title":"Schizophrenia","volume":"334","author":"Kane","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/S0006-3223(00)01026-X_BIB20","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive and Negative Syndrome Scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"10.1016\/S0006-3223(00)01026-X_BIB21","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/BF02245602","article-title":"Mechanisms of action of atypical antipsychotic drugs","volume":"124","author":"Kinon","year":"1996","journal-title":"Psychopharmacology"},{"key":"10.1016\/S0006-3223(00)01026-X_BIB22","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3928\/0048-5713-19960701-10","article-title":"The relationship between clozapine plasma levels and clinical response","volume":"26","author":"Lindenmayer","year":"1996","journal-title":"Psychiatr Ann"},{"key":"10.1016\/S0006-3223(00)01026-X_BIB23","unstructured":"Malhotra AK, Pinsky DA, Breier A (1996): Future antipsychotic agents: Clinical implications. In: Breier A, editor. The New Pharmacotherapy of Shizophrenia. Washington, DC: American Psychiatric Association Press, 41."},{"key":"10.1016\/S0006-3223(00)01026-X_BIB24","doi-asserted-by":"crossref","unstructured":"Martin J, Gomez JC, Garcia-Bernardo E, Cuesta M, Alvarez E, Gurpegui M, Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia (1997): Olanzapine in treatment-refractory schizophrenia: Results of an open-label study. J Clin Psychiatry 58:11.","DOI":"10.4088\/JCP.v58n1103"},{"key":"10.1016\/S0006-3223(00)01026-X_BIB25","doi-asserted-by":"crossref","unstructured":"Meltzer HY (1989): Clinical studies on the mechanism of action of clozapine: The dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 99(suppl):S18\u2013S27.","DOI":"10.1007\/BF00442554"},{"key":"10.1016\/S0006-3223(00)01026-X_BIB26","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/schbul\/17.2.263","article-title":"The mechanism of action of novel antipsychotic drugs","volume":"17","author":"Meltzer","year":"1991","journal-title":"Schizophr Bull"},{"key":"10.1016\/S0006-3223(00)01026-X_BIB27","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1192\/S0007125000296876","article-title":"The importance of serotonin-dopamine interactions in the action of clozapine","volume":"160","author":"Meltzer","year":"1992","journal-title":"Br J Psychiatry"},{"key":"10.1016\/S0006-3223(00)01026-X_BIB28","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/0010-440X(94)90164-3","article-title":"Clozapine\u2019s effect on negative symptoms in treatment-refractory schizophrenics","volume":"35","author":"Miller","year":"1994","journal-title":"Compr Psychiatry"},{"key":"10.1016\/S0006-3223(00)01026-X_BIB29","first-page":"886","article-title":"The European experience with use of clozapine","volume":"41","author":"Naber","year":"1990","journal-title":"Hosp Community Psychiatry"},{"key":"10.1016\/S0006-3223(00)01026-X_BIB30","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/BF02245615","article-title":"Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine\u2014a 123I IBZM single photon emission tomography (SPET) study","volume":"124","author":"Pilowsky","year":"1996","journal-title":"Psychopharmacology"},{"key":"10.1016\/S0006-3223(00)01026-X_BIB31","first-page":"315","article-title":"A comparison of European and American dosing regimens of schizophrenic patients on clozapine","volume":"31","author":"Pollack","year":"1995","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/S0006-3223(00)01026-X_BIB32","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1002\/(SICI)1097-0258(19980815\/30)17:15\/16<1703::AID-SIM972>3.0.CO;2-G","article-title":"Therapeutic equivalence investigations","volume":"17","author":"Rohmel","year":"1998","journal-title":"Stat Med"},{"key":"10.1016\/S0006-3223(00)01026-X_BIB33","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/archpsyc.1982.04290040080014","article-title":"Research diagnoses for tardive dyskinesia","volume":"39","author":"Schooler","year":"1982","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/S0006-3223(00)01026-X_BIB34","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/S0006-3223(00)01026-X_BIB35","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1176\/ajp.154.4.466","article-title":"Negative symptoms","volume":"154","author":"Tollefson","year":"1997","journal-title":"Am J Psychiatry"},{"key":"10.1016\/S0006-3223(00)01026-X_BIB36","doi-asserted-by":"crossref","unstructured":"Tran PV, Dellva MA, Tollefson GD, Beasley CM Jr, Potvin JH, Kiesler GM (1997): Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry 58:205\u2013211.","DOI":"10.4088\/JCP.v58n0505"},{"key":"10.1016\/S0006-3223(00)01026-X_BIB37","unstructured":"U.S. Food and Drug Administration (1990): COSTART Coding Symbols for Thesaurus of Adverse Reaction Terms. Rockville, MD: U.S. Food and Drug Administration."},{"key":"10.1016\/S0006-3223(00)01026-X_BIB38","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3928\/0048-5713-19861001-07","article-title":"Causes of neuroleptic noncompliance","volume":"16","author":"Weiden","year":"1986","journal-title":"Psychiatr Ann"}],"container-title":["Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000632230001026X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000632230001026X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T01:10:14Z","timestamp":1578877814000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000632230001026X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,1]]}},"alternative-id":["S000632230001026X"],"URL":"https:\/\/doi.org\/10.1016\/s0006-3223(00)01026-x","relation":{},"ISSN":["0006-3223"],"issn-type":[{"value":"0006-3223","type":"print"}],"subject":[],"published":{"date-parts":[[2001,1]]}}}